SCHEMBL1094876

SCHEMBL1094876

O=S(=O)(Nc1ncc(F)s1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.52
CA1 P00915 2/20 0.50
CA12 O43570 1/20 0.50
CA2 P00918 1/20 0.50
CA3 P07451 1/20 0.50
CA6 P23280 1/20 0.50
CA5A P35218 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
CA5B Q9Y2D0 1/20 0.50
ATM Q13315 1/20 0.49
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
SCN1A P35498 2/20 0.47
SCN5A Q14524 2/20 0.47
SCN8A Q9UQD0 2/20 0.47
CCNE2 O96020 1/20 0.46
CCNE1 P24864 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15342920 0.84 CA1 (0.52) SCN9ACA1CA2ALDH1A1GAA
SCHEMBL3061891 0.83 SCN3A (0.50) SCN9ACA1ATMLMNASCN1A
SCHEMBL3477829 0.81 SCN8A (0.55) SCN9AATMALDH1A1LMNAGAA
SCHEMBL14921838 0.81 ALDH1A1 (0.54) SCN9ACA1CA12CA2CA3
SCHEMBL6504893 0.81 CA1 (0.54) CA1CA12CA2CA3CA6
SCHEMBL1094463 0.81 CA1 (0.50) CA1CA12CA2CA3CA6
SCHEMBL16177959 0.80 SCN9A (0.55) SCN9ACA1CA2CA9
SCHEMBL15258618 0.80 SCN9A (0.54) SCN9A
SCHEMBL1094236 0.76 SCN8A (0.50) SCN9ASCN1ASCN5ASCN8A
SCHEMBL25349874 0.76 LMNA (0.66) CA1CA12CA2CA3CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 SCN9A 73/4885CA1 1355/4885CA12 1165/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 SCN9A 73/4885CA1 1355/4885CA12 1165/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 SCN9A 73/4885CA1 1355/4885CA12 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.